Leukemia inhibitory factor

The Retinal Degeneration Fund Announces an Investment in NVasc

Retrieved on: 
Monday, October 16, 2023
Acquisition, Doctor of Philosophy, Visual impairment, VEGF, Survival, Disease, IL-6, AMD, Nobel, Leukemia inhibitory factor, Growth, Colic flexures, Cytokine, Lasker, Research, Geographic atrophy, Pharmaceutical industry, MD

RALEIGH, N.C., Oct. 16, 2023 /PRNewswire/ --Today, the RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research to advance preventions, treatments, and cures for retinal degenerative diseases, announces an investment in NVasc, an early-stage company focused on treating age-related macular degeneration (AMD).

Key Points: 
  • RALEIGH, N.C., Oct. 16, 2023 /PRNewswire/ --Today, the RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness aimed at rapidly driving research to advance preventions, treatments, and cures for retinal degenerative diseases, announces an investment in NVasc, an early-stage company focused on treating age-related macular degeneration (AMD).
  • The financing supports continued product and nonclinical development of NVasc's technology for therapeutic angiogenesis as a treatment for retinal ischemia associated with age-related macular degeneration and geographic atrophy.
  • Adrienne Graves, PhD, RD Fund Chair, joined the NVasc board as an independent board director.
  • Dr. Graves, chair of Iveric Bio prior to its acquisition by Astellas, brings a wealth of Board governance experience to NVasc."

New Study Finds Mouse Embryonic Stem Cells Have No Special Requirement for Threonine

Retrieved on: 
Wednesday, September 7, 2022
Threonine, Leukemia inhibitory factor, LIF, Experimental biology, Experimental Biology and Medicine, DRS, Methionine, Protein, Society for Experimental Biology and Medicine, Glutamine, State university system, Publishing, Serum, Stem cell, Biophysics, Department, Arginine, Cell, Organic acid, GLOBE, Physiology, Growth, Valine, Society, Vaccine, Medicine, MESC

The study, led by Dr. Jian Feng in the Department of Physiology and Biophysics at the State University of New York, Buffalo, finds that mouse embryonic stem cells do not have a unique requirement for threonine.

Key Points: 
  • The study, led by Dr. Jian Feng in the Department of Physiology and Biophysics at the State University of New York, Buffalo, finds that mouse embryonic stem cells do not have a unique requirement for threonine.
  • An influential study published in 2009 claims that the growth and proliferation of mouse embryonic stem cells (mESCs) have a unique dependence on threonine.
  • It has become accepted that mESCs have a special requirement for threonine to grow and multiply.
  • The present study thus set the record straight on the amino acid requirement of mESCs by finding that, just like most types of cells, mESCs do not have a special requirement for threonine.

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting

Retrieved on: 
Monday, October 18, 2021
Gastric lavage, EMA, Exo, Cell, Microsoft, NTFS, LPS, Sev Ohanian, Amphiregulin, California Institute for Regenerative Medicine, Respiratory disease, European Medicines Agency, Poster, National, CIRM, Mortality, Therapy, MS, HGF, FDA, Exosome, Multiple sclerosis, Orphan drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurodegeneration, Food, Phrase, Hepatocyte growth factor, Amyotrophic lateral sclerosis, Company, MSC, Annual report, Brainstorm, California, LIF, AREG, Regenerative medicine, Safety, NASDAQ, Leukemia inhibitory factor, Research, BALF, TSG-6, Pharmaceutical industry, Medical imaging, Vaccine

The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Artificial Intelligence-formulated dietary supplement blend supports healthy cell renewal

Retrieved on: 
Thursday, February 27, 2020
Branches of biology, Biology, Life sciences, Developmental biology, Stem cells, Biotechnology, Oncology, Leukemia inhibitory factor, Cellular differentiation

Fort Lauderdale, Fla.-based Life Extension has partnered with Insilico Medicine, Inc., headquartered in Rockville, MD, to utilize artificial intelligence to formulate GEROPROTECT Stem Cell, a dietary supplement which helps maintain youthful, healthy stem cell function.

Key Points: 
  • Fort Lauderdale, Fla.-based Life Extension has partnered with Insilico Medicine, Inc., headquartered in Rockville, MD, to utilize artificial intelligence to formulate GEROPROTECT Stem Cell, a dietary supplement which helps maintain youthful, healthy stem cell function.
  • GEROPROTECT Stem Cell encourages balanced stem cell differentiation and self-renewal with nutrients that promote healthy stem cell function, cellular protein regulation, DNA health, AMPK signaling, and more.
  • GEROPROTECT Stem Cell can be taken by itself, with other GEROPROTECT Life Extension products (Ageless Cell and Longevity A.I.).
  • GEROPROTECT Stem Cell can also be paired with Senolytic Activator from Life Extension for enhanced youthful cellular health support.

Global Recombinant Cell Culture Supplements Market: Focus on Recombinant Supplement Products, Applications, and Region - Analysis and Forecast: 2018 to 2028

Retrieved on: 
Wednesday, December 12, 2018
Cytokines, Leukemia inhibitory factor, Oncology, Pharmacology

Other factors include rising investment in the R&D of life sciences and increasing demand for cell culture supplements.

Key Points: 
  • Other factors include rising investment in the R&D of life sciences and increasing demand for cell culture supplements.
  • In 2017, which application area had the largest share and the fastest growth rate in the global recombinant cell culture supplements market?
  • The global recombinant cell culture supplements market was valued $230.5 million in 2017 and is anticipated to reach $788.6 million by 2028.
  • The global recombinant cell culture supplements market is segmented into three different parts: by products, by application, and by region.